# A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering Medications

Study · id `cardio:ct-nct07889648` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07889648](<https://clinicaltrials.gov/study/NCT07889648>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07889648

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 948 participants.

## Technical summary

Registry record NCT07889648. Randomized; no masking; primary purpose treatment. Start 2026-12-01 (anticipated); primary completion 2029-04-02 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 948 participants (planned count; ClinicalTrials.gov record NCT07889648, source copy `cardio:ctgov-nct07889648-2026-10-22`, retrieved 2026-10-26)
- Planned start: 2026-12-01 (anticipated) (ClinicalTrials.gov record NCT07889648, source copy `cardio:ctgov-nct07889648-2026-10-22`, retrieved 2026-10-26)
- Primary completion: 2029-04-02 (anticipated) (ClinicalTrials.gov record NCT07889648, source copy `cardio:ctgov-nct07889648-2026-10-22`, retrieved 2026-10-26)
- Completion: 2029-04-23 (anticipated) (ClinicalTrials.gov record NCT07889648, source copy `cardio:ctgov-nct07889648-2026-10-22`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07889648-2026-10-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering Medications
- Acronym: ENI-SPIRE-2
- Condition: Type 2 Diabetes Mellitus
- Intervention (Combination product): Enicepatide
- Intervention (Combination product): Tirzepatide
- Lead sponsor: Hoffmann-La Roche
- Lead sponsor class: INDUSTRY
- Collaborator: Chugai Pharmaceutical
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Tirzepatide (`cardio:tirzepatide`)
- Registry lists this organization as the lead sponsor: Hoffmann-La Roche (`cardio:org-hoffmann-la-roche`)

## Provenance

Content hash: e468e4578ef5b97e609d3e47cc03b881750b2b312ccab4bba53c33bc34b3c27e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
